Key Stats for Caris Life Sciences Stock
- Price Change: +4.6%
- Current Price: $20.13
- Street Target Price: $36.70
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Caris Life Sciences (CAI) is gaining momentum, with shares rallying 4.6% to $20.13 following a record-breaking fourth quarter earnings release that highlighted the company’s rapid transition into a profitable TechBio powerhouse.
The molecular profiling leader delivered fourth quarter revenue of $293 million, representing a massive 125% increase year over year.
Management highlighted its core Molecular Profiling segment, which saw service revenues surge 199% during the quarter to $282 million.
Vice Chairman Brian Brille detailed exactly why the company’s unique profitability profile provides a massive competitive advantage.
Brille stated verbatim: “This strong profitability profile is unique in our industry and provides valuable strategic flexibility for ongoing investment in our tech platform for new products.”
The company also unveiled impressive interim data from its ACHIEVE-1 study for “Caris Detect,” a whole-genome sequencing-based early cancer detection test.
The test demonstrated a 63.1% sensitivity for Stage I and II cancers combined with a 99.1% specificity in asymptomatic screening populations.
See analysts’ growth forecasts and price targets for Caris Life Sciences stock (It’s free!) >>>
Is Caris Life Sciences Undervalued Today?
Aggregated analyst data indicate that Wall Street is highly bullish on the company’s ability to dominate both the therapy selection and early detection markets.
The consensus Street target price of $36.70 represents an attractive 82.3% potential return from the current $20.13 baseline.
The company ended 2025 with over $800 million in cash on hand, allowing it to aggressively fund the upcoming Q2 2026 launch of Caris Detect.
CFO Luke Power explained exactly how the company’s scaling average sales price (ASP) is driving record financial results.
Power stated verbatim: “This has resulted in us being able to reach an ASP for our 2025 cases of $3,876 per tissue and just above $2,500 for our blood assay.”
Read the full Caris Life Sciences Transcript on TIKR to see the 2026 blockbuster guidance >>>
Valuation Deep Dive
The TIKR Analyst Breakdown identifies Caris Life Sciences as a dominant molecular data leader successfully leveraging its massive clinical database to drive long-term profitability.
- Street Target Price: $36.70
- Current Price: $20.13
- Implied Upside: 82.3%
The Molecular Data Moat: Caris has built one of the most powerful genomic resources in the world, recently surpassing 1 million profiled cases. This vast data set features over 627,000 exomes and 678,000 transcriptomes, creating a proprietary engine for AI model development that small gene panels cannot match.
Path to Blockbuster Status: The commercial engine is operating at peak efficiency, with therapy selection volumes growing 22% in 2025. Management has provided a robust 2026 outlook, projecting total revenue between $1.0 billion and $1.02 billion. By maintaining positive free cash flow while investing $60 million in new capacity, Caris is positioned to bend the cancer mortality curve while compounding shareholder value.
Conclusion: A revitalized precision medicine leader successfully leveraging massive revenue growth and breakthrough early detection data to accelerate its path to $1 billion in annual sales. Caris Life Sciences offers a steady path to significant long-term appreciation. The path to the $36.70 target is paved by record ASP execution, the 1 million case data milestone, and the upcoming launch of Caris Detect.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Caris Life Sciences?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Caris Life Sciences, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Caris Life Sciences alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
[Analyze Caris Life Sciences on TIKR Free →]
Looking for New Opportunities?
- See what stock billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
